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Valid estimates of pacemaker reliability are necessary so that 
physicians can be notified promptly of potential problems. 
Precise stimates of reliahiiity require prolonged follow-up of 
many patients (1); for this reason, estimates of device perfor- 
mance are generated predominantly b  the device manufac- 
t!lrers with the use of implant registration data and returned 
product analysis (I-6). If a pa:ient dies, the matrufacture: may 
not be notified and the pnerator not returned, unless pace- 
maker malfunction is suspected. Elderly patients may also be 
lost to follow~up and fail to have their device checked rcgu- 
larly. If adjustment is not made for this loss of follow-up, 
optimistic estimates of device performance may be generated 
by actuarial methods (1). The practice among manufacturers 
varies, with some adjusting generator survival curves for ex- 
pected patient mortality and loss of follow-up (3,4,6) and 
others making no adjustment for these factors (2,s). The aim 
of this study was to determine the importance: of ignoring loss 
of follow-up data in a cohort of patients at risk for premature 
pacemaker failure. 
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of causes unrelated to the 
S 
situ etween December 1989 and March 1992, 
73 patients (40 men, 33 women; mean [ +SD] age 77 ‘c 8 years) 
underwent i itial implantation f a single-chamber, v ntricular 
non-rate-responsive pacemaker (Reflex 8220; Teletronics, 
Sydney, Australia). The indication for pacemaker implantation 
was heart block (n = 51), sick sinus syndrome (n = 21) and 
undiagnosed syncope (n = 1). In general, a ventricular- 
inhibited (VVI) device was recommended when the patient 
was elderly and had limited mobility or life expectancy, or both. 
Six patients had two successive implantations of the Reflex 
8220 device: therefore, a total of 79 devices were followed up. 
Follow-up was performed at a pacemaker clinic at 6- to 
12-month intervals. Telephonic contact was made if a patient 
failed to attend the clinic. No patient was lost o follow-up, but 
device status could not be determined for one patient who 
declined to attend the clinic. Mean follow-up time was 18.6 + 
10 months, with a total follow-up time of 122 patient-years. 
Survival analysis. Pacemaker survival curves were first 
generated bythe Kaplan-Meier method (7), with censoring at
the time of death (23 patients) or elective xplantation f a 
normally functioning device (five devices). To examine the 
effect of ignoring censoring, patient mortality was then ig- 
nored, and follow-up was assumed to continue to the date of 
analysis (September 1993). Censoring for elective explantation 
was maintained. The effect of differing censoring and device 
failure rates was stsdied by varying these while fitting Weibull 
JACC Vol. 24, No. 4 
October 1994:10?8-x1 
LElTCH ET AL. 
BIAS IN PACEMAKER RELlABlLIW ESTIMATES 
1079 
Nonths 
gurc 1. §ur+al of the Rellc~ 8220 device. The lower CMWC sl~c~ws 
6 true survival function wit il median failure time of just >3 )k%li3 
(37 months). Also shown (III) L!r CMWC) is the il~~~~it~~lll Kaplan-Mcier 
ctnve for pacemaker stkval if patient mortality is ignored. 
and exponential models using the Stata statistical package (8). 
The Weibull model is a generalization of the exponential 
model that is often used for modeling survival data. Unlike a 
Kaplan-Meier curve, it is mathematically simple and thus 
permits explorations of the hypothetic effects of degrees of 
censoring (see Appendix). 
Thirteen pacemakers were explanted because of premature 
failure. Pacemaker survival is shown in Figure 1. The time to 
pacemaker failure closely followed a Weibull distribution with 
coefficients h = 0.0239 and p = 2.97, giving a median failure 
time of 37 months.* Also shown in Figure 1 is the survival 
estimate when censoring is ignored (apart from elective ex- 
plantations) and follow-up is assumed to continue to the time 
of analysis. Although the timing and number of failures are 
unchanged, pacemaker survival is substantially biased, with 
30.month survival calculated at 80 -C 11% and 28 patients till 
being “followed up,” in contrast o the correct estimate of 
63 _’ 18% and only 8 patients till at risk of failure. The 
apparent duration of follow-up is inflated from 122 to 188 
patient-years (Fig. 2). 
Twenty-three of the 73 patients died (none from pacemaker 
failure), for a survival rate of 53 ? 18% at 3 years (Fig. 3). The 
best exponential fitto this curve (also plotted) has an estimated 
rate of A = 0.0156 deaths/month, with a median patient 
survival time of ln(2)lA = 44.3 months. This is the median 
ignored censoring time in the analysis of pacemaker survival, 
and the ratio of median failure time to median ignored 
censoring time is therefore 37/44.3 = 0.835. Because a large 
~~~~~e 2. Effect of ignoring censoring on apparent follow-up time. The 
Iots show months of foliow-up. In total, follow-up time increased 
from the Xtllill 122 patient-years to an apparent 188 patient-years. 
median time implies a small failure rate, this means that the 
rate of censoring by death is less than the rate of pacemaker 
failure, but not much less. 
To examine the effect of different censoring and failure 
rates, survival curves were modeled by varying Ihe ratio of 
median failure time to median censoring time from 0 (no 
ignored censoring) to i.0 (severe ignored censoring) (Fig. 4). 
The failure time was assumed to follow a Weibull distribution 
with a shape variable p = 3, similar to our data. Figure 4 
demonstrates the substantial differences in survival estimates 
that emerge from the median survival onward, with increasing 
inaccuracy as the censoring rate approaches the failure rate. 
Figure 3. Patient surviva! and thL; tilted exponeiltial (A = 0.0156) 
model of survival. Median patient survival time was only 44 months, 
slightly longer than the median pacemaker survival time of 37 months, 
and the ratio of median censoring/failure was therefore 0.84. 
0-j 
*The Weibull survival function is S(t) = exp{-(At)P), with median survival I I 
I I 
0 IO 30 4b 
time to.5 = [In(2)(““‘]/A. k&l.3 
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4, Model of the effects of ignoring censoring. The timc units 
edidn pccmaker survival time. Thus, fur our data with the R&x 
unit would he 37 months. which corresponds 10 
line). “I’hc llwvest curve is the true pacemaker 
suurvival function, which is a Weihull distribution with a shape variahlc 
of p = 3 to match our experience. The live curves have median ntios 
of failure time tu censoring time of 0.0 (true curve), 0,25,05,0.75 and 
1.0. High values (~0.5) imply serious overestimation uf the fraction 
surviving at any time. Fur example, at 1.5 times the median survival, 
the true projected pacemaker survival is -10%. If censoring is ignored, 
and the ratio of censoring to failure is 0.75 (similar to our data), then 
the survival estimate would he crrancously calculated at -47%. 
discussion 
It is difficult fur individual pacemaker ccrlters to dctcrminc 
paccmuker reliability bccausc they may have limited experi- 
cncc with each dcvicc: model. and failures arc generally 
infrequent. Consequently, physicians may rely on the manu- 
facturer’s estimate of device performance in evaluating the risk 
of premature failure. This estimate is potentially inaccurate 
beeaua it is generated fmm returned product analysis and 
implant registration data; bias may result from incomplete 
ascertainment of failures and from overestimation of follow-up 
time. During the warranty period (generally 25 years) cx- 
planted devices are usually returned to obtain credit, and there 
is probably fairly complete ascertainment of failures. As our 
data show, overestimation of follow-up is a potentially serious 
source of bias even after zlatively short periods of follow-up. 
m does boss uf censoring hlsely reduce the failure rate? 
Survival analysis proceeds by calculating, in successive intervals 
of time, the ratio of failures to total cases. If a patient is lost to 
follow-up, the correct failure estimate can still be calculated by 
censoring the patitint. This procedure reduces the total number 
of caxs in the succeeding time intenrals and, although the 
precision of the survival estimate is reduced, the ratio of 
failures to total cases is not biased. However, if there is loss of 
follow-up that is not reported, the total number of cases at 
subsequent ime intenrals will be erroneously large, and the 
ratio of failures to total cases will be erroneously small. In 
effect, if a patient’s death is not reported to the manufacturer, 
that patient’s pacemaker will be counted in each successive 
interval as functioning normally. Clearly, this will bias the 
survival estimate because a proportion of these pacemakers 
were destined to fail. 
My. The main cause of censoring in this 
elderly patient cohort was death unrelated to the pacemaker 
system. The mortality rate in this study was substantially higher 
than that reported in other series (9-l l), possibly because of 
the select nature of this cohort with a mean age of 77 years. 
The survival rate of octogenarians with pacemakers is poor 
(12) and significantly worst than that of age- and gender- 
matched control subjects. V~ria~~cc in mortality is a problem 
when dcvicc survival curves are adjusted empirically to account 
for unrcportcd loss of follow-up. Adjustments used include an 
attrition rate of 13.5% in the first ycitr and 9.5% thcrcaftcr (4), 
a constant rate of 6%/year (I) and a constant rate of IO%/ycar 
(6). Probably the use of mortality rates from age- and gcndcr- 
matched demographic data is most appropriate because, al- 
though the survival rate of patients with pacemakers is slightly 
worse than these rates (IO), the diffcrenccs are small. 
~~rna~e~ survival. In our study, pacemaker survival 
was also poor. By contrast, the Bilitch report (13). an 
indcpcndent multicenter report of pdccmaker performance 
(14), found that the Reflex 8220 device bad a 94 It 7% 
survival rate at 3 years. This finding suggests that other 
factors, such as exccssivc torque applied to the set screws at 
the time of implantation, arc important determinants of 
failure with this dcvicc. A lower than expected pacemaker 
survival time has several effects on this analysis. First, over 
the entire pacemaker lifetime, poor paccmakcr survival 
diminishes the bias from unreported patient mortality. For 
instance, if the median pacemaker survival time was a more 
usual 7 to 8 years and patient survival time was unchanged 
(median 3.7 years), most patients would die before their 
pacemaker failed. Ignoring this mortality would result in 
grossly inflated estimates of pacemaker survival. In contrast. 
because the curves diverge most noticeably after the median 
device survival time (Fig. 4), a better pacemaker survival 
time would result in less bias during the more critical early 
years of follow-up. 
Limitations and conclusions. Pacemaker failure in other 
settings may follow a distribution different from that of the 
Weibull model that best fitted our data. Nevertheless, 
whatever the mode and timing of device failure, survival 
curves that arc generated solely from implant registration 
data and returned product analysis result in inflated esti- 
mates of device performance. The degree of bias depends on 
the relative rates of death and pacemaker failure and is 
worst when patient mortality rates are high in comparison 
with the pacemaker failure rate. Whenever possible, an 
adjustment should be made for unreported patient deaths. 
Even then, device performance estimates should be inter- 
preted cautiously because the statistical assumptions may be 
inaccurate and ascertainment of failures may be incomplete. 
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When faihrrcs occur r~~l~d~)ll~l~ according to a ~r~~~~~ili~ distribution. that 
distribution can bc described by several equivalent functions, of which 
perhaps the most familiar is the survival function S(t). This is the function 
that is estimated from data using the method of Kaplan and Icier (7). An 
nltcmativc rcprcscntation of tbc same ~~~~tr~l~Mt~~~~~ is the density function, 
usuoily denoted by f(t), which describes tbc rate at which events ;Lrc 
observed over time. S(t) is rcluted to f(t) by the following integral: 
Suppose thnt ;tn unknown Survivnl CIIIVC S(t) is to be cstimntcd from datn, 
tbnt censoring is mistakenly ignored ;md that this cxxsoring occurs 
ru~ldomly i\cc<>rdLg to i1 WIW~V;~ function C(t). ‘I%C r;tte nt which failures 
nrc ohselvcd will then bc reduced from f(t) to f(t)C( t) bccuusc the 
numbcr of pitdents ;IP risk of frtihtrc A uny lime will hc in proporlion IO 
their chitnccs of rrol having yut hocn ccnsorcd. The ibppiWflt survival 
CIIIVC, S*(t), Ci\ll thus bL’ CidClhtCd US@ il lll~l~~i~~ciIti(~~l of cqu;ltion I: 
PI 
It is this curve that will be estimated by a Kaplan-Icier culvc that is 
calculated taking no XCOUII~ of the censoring. Wc hihve investigated the 
e&t of various dgrecs of censoring C(t) due to unreported dcilth of 
patients by the use of numeric integration of equation 2. 
I. Kim JS, Madison L. Estimation of lield performance for implantlrble medical 
products. In: Proceed& of the Biopharmaceuticul section of the American 
Srntislical Association. American StutisIical Association. lY90;254-Y. 
2. irnermedics product pcr~ormance report. Houston (TX): iintermcdic~, ~nc. 
Murch 1992. 
3. Product performance reporl. Minneapolis (MN): MedIronic, Inc, February 
lYY3. 
4. Siemens Pacesrlter pulse generator performance report. Sylmar (CA): 
Siemens RIcesetter. Inc. January 1YY3. 
5. Telctronics pacing systems reliability report. Sydney, Australia: Telcrronics, 
Inc, July lYY3. 
0. Product pcrformancc report. St. Paul (MN): Cardiac Pacemakers, Inc, 
December lYY2. 
7. Kaplnn EL, Meier P. Nonpxunetric estimation from incomplete ohsemit- 
lions. J Am St;n Ahsoc lYS8;53:457-82. 
8. Stiila Rcfcrcncc M~~mXd. Ilele#X 3 Icomputer program). College Slalion 
(TX): SIuIu C’orporinion, lYY3. 
0. Mullcr C, Ccrnin J, Glognr D, ct ul. SIIn&;ll r;Itc ;md CBIISL’S d dciltb in 
pillicntb will1 p;tccm;Ikers: depcndencc on symptoms leading to p;lccm;lkcr 
irllpliIIltiltiolI. Eur Heart J IYKH;Y: 1003-Y. 
IO. Alt E, Volkcr R, Wirtzfeld A. IJlm K. Survival xnd followup after pxcm;~ker 
impl;mt:nion: iI comp;~rison of pntienls with sick sinus Ayndromc, complctc 
hcaF( block, and ;Itrial librillution. PACE lYllS;X:S4Y-!i5. 
1 I. Zunini 11, Fncchinelli A. Gallo G, cl al. SurviviIl rates after pacemaker 
implantation: u study of patients paced for sick sinus syndrome and 
atrioventricular block. PACE lYHY;l2:ll165-Y. 
12. Shen WK. Hummill SC, Hayes DE, Packer DL, Bailey KR, Gcrsb BJ. Long 
term survival after pacemaker implantation for degenerative conduction 
disc;Ise [;Ibstrucl]. Circulation iYY2;Xh S~ppl i:l-4.50. 
1.1. Sung S. The Bilitch report: part A. Performance of implantable cardiac 
rhythm devices. PACE lOY3;lh:Hl4-21. 
14. Furman S. The Bilitch registry. PACE 1903: lh:l37. 
